SCHEMBL23795282

SCHEMBL23795282

CC(O)(CC(C)(c1ccccc1)c1ccc(Cl)cc1)c1ccc(Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.48
BCL2 P10415 1/20 0.46
HTT P42858 4/20 0.42
NPSR1 Q6W5P4 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
MAPK1 P28482 2/20 0.42
XBP1 P17861 1/20 0.42
KIF11 P52732 2/20 0.41
LMNA P02545 2/20 0.40
TSHR P16473 1/20 0.39
HIF1A Q16665 1/20 0.39
CYP19A1 P11511 1/20 0.39
CHRM2 P08172 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
CHRM1 P11229 1/20 0.38
DRD1 P21728 1/20 0.38
TBXA2R P21731 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23795276 1.00 KMT2A (0.51) KMT2AMEN1BCL2HTTNPSR1
SCHEMBL23795271 0.89 CYP2C19 (0.44) KMT2ASMN1; SMN2MAPK1HIF1AALDH1A1
Fenpentadiol SCHEMBL48969 0.79 KMT2A (0.58) KMT2AMEN1BCL2HTTNPSR1
SCHEMBL3197683 0.78 CYP2C19 (0.48) KMT2ASMN1; SMN2MAPK1LMNAHIF1A
SCHEMBL28209460 0.77 NPSR1 (0.56) KMT2AMEN1BCL2HTTNPSR1
SCHEMBL4062666 0.77 KMT2A (0.82) KMT2AMEN1BCL2HTTNPSR1
SCHEMBL16144309 0.77 KMT2A (0.82) KMT2AMEN1BCL2HTTNPSR1
SCHEMBL9906175 0.77 KMT2A (0.82) KMT2AMEN1BCL2HTTNPSR1
SCHEMBL3836889 0.76 KMT2A (0.53) KMT2AMEN1BCL2HTTNPSR1
SCHEMBL11045361 0.75 CYP2C19 (0.43) KMT2AMEN1SMN1; SMN2MAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12127473-B2 Di-, tri- and tetraphenylindane derivates and their use in organic electronics DOTTIKON ES HOLDING AG (CH) 2024-10-22 US disclosed
US-20220006020-A1 DI-, TRI- AND TETRAPHENYLINDANE DERIVATES AND THEIR USE IN ORGANIC ELECTRONICS DOTTIKON ES HOLDING AG (CH) 2022-01-06 US disclosed
EP-3877357-A1 DI-, TRI- AND TETRAPHENYLINDANE DERIVATIVES AND THEIR USE IN ORGANIC ELECTRONICS DOTTIKON ES HOLDING AG (CH) 2021-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220006020-A1 DI-, TRI- AND TETRAPHENYLINDANE DERIVATES AND THEIR USE IN ORGANIC ELECTRONICS NR0B2, KCNJ2, TRRAP KMT2A 1970/4885MEN1 2154/4885BCL2 2771/4885
US-12127473-B2 Di-, tri- and tetraphenylindane derivates and their use in organic electronics NR0B2, KCNJ2, TRRAP KMT2A 1970/4885MEN1 2154/4885BCL2 2771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.